CSN9 signalosome inhibits SCFFbxo7-mediated CRBN degradation, thereby promoting the sensitivity of myeloma cells to IMiDs (Sievers et al., 2018; Liu et al., 2019). The gene discussed is CRBN; the disease is plasma cell myeloma.